PathoBrainSeq extracts blood cells from patients and uses Whole Genome Sequencing (WGS) and single-cell RNA sequencing (scRNA-seq) to achieve ultra-precision diagnosis of brain diseases — identifying what other platforms cannot.
From a simple blood draw, we extract immune cells and apply WGS and scRNA-seq to detect molecular signatures of neurodegeneration — years before clinical symptoms appear.
Our platform integrates multi-omics data with digital biomarker testing to deliver the most comprehensive neurological health picture available.
The first platform to combine WGS + scRNA-seq + digital biomarkers for multi-disease neurological profiling.
We are in pre-launch phase. These are the transformative impacts we anticipate — and that scientists, clinicians, and advocates are eagerly awaiting.
Online-based brain disease screening tool — quickly classify neurodegenerative disease categories before in-depth NeuroMap genomic analysis.
Select your disease focus, complete a battery of validated digital biomarker tests, and track results longitudinally. Designed for patients, caregivers, and healthcare providers.
PathoBrainSeq is in active research and pre-commercial phase. We are transparent about what is live, what is in development, and what's on our roadmap.
Our current pilot dataset includes 3 non-AD controls, 4 early AD, and 3 late AD patients. We are actively accepting research collaborations, pilot study partnerships, and early clinical inquiries for AD and Dementia screening.
Motor biomarker validation, LRRK2/GBA/HTT genetic panel development, and scRNA-seq signature identification ongoing.
Planned for Phase 2 expansion following core AD/PD/HD platform validation and series A funding.
Early precision diagnosis of neurodegenerative diseases through blood-based WGS & scRNA-seq genomic analysis — detecting disease-causing mutations and monitoring progression before symptoms appear.
WGS provides comprehensive coverage of the entire genome — detecting disease-causing mutations, structural variants, and pharmacogenomic markers that targeted panels miss.
scRNA-seq goes beyond genetics — measuring which genes are actually active in each individual cell at the time of sampling, revealing disease progression dynamics invisible to WGS.
A team of seasoned neuroscientists, bioinformaticians, and clinicians united by a mission to revolutionize brain disease diagnosis.
We believe that ultra-precision neurological diagnostics — combining WGS, scRNA-seq, and digital biomarkers — should be accessible to patients and clinicians everywhere.
Brain diseases like Alzheimer's have seen decades of drug development failures — primarily because we haven't had the molecular tools to select the right patients. PathoBrainSeq is building those tools.
Whether you're a patient, clinician, researcher, pharma partner, or investor — we want to hear from you.
We're building the future of neuro-diagnostics — and we need collaborators, patients, clinicians, and partners. Every conversation matters.